No significant change in oxygen requirement was seen with vasodilator therapy initiation.

When given via the inhaled route it is a selective pulmonary vasodilator.

H is not useful as an adjunct vasodilator therapy for CILD-PH patients.

Prostacyclin is a powerful vasodilator and inhibits platelet adhesion and cell growth.

PGI2 acts as a vasodilator and a potent inhibitor of platelet aggregation.